Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 4/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HMOX1 | P09601 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751891 | 0.91 | HMOX1 (0.53) | TBXAS1CYP19A1HMOX1 | |
| SCHEMBL4823867 | 0.90 | TBXAS1 (0.48) | TBXAS1CYP19A1KMT2ACYP17A1HMOX1 | |
| SCHEMBL2347295 | 0.86 | CYP17A1 (0.60) | TBXAS1CYP19A1CYP17A1 | |
| SCHEMBL6752974 | 0.84 | HMOX1 (0.51) | TBXAS1CYP19A1HMOX1 | |
| SCHEMBL6753943 | 0.81 | HMOX1 (0.53) | TBXAS1CYP19A1HMOX1 | |
| SCHEMBL10463554 | 0.79 | TBXAS1 (0.57) | TBXAS1CYP19A1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL6174346 | 0.79 | HRH3 (0.60) | TBXAS1CYP19A1 | |
| SCHEMBL8609686 | 0.76 | CYP17A1 (0.76) | TBXAS1CYP19A1KMT2ACYP17A1HMOX1 | |
| SCHEMBL4819893 | 0.76 | CYP17A1 (0.56) | TBXAS1CYP19A1CYP17A1 | |
| Hydrochloric Acid SCHEMBL8610701 | 0.75 | CYP17A1 (0.74) | TBXAS1CYP19A1KMT2ACYP17A1HMOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | TBXAS1 702/4885CYP19A1 2367/4885KMT2A 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.